Why do drugs work in CLL?

Leukemia and Lymphoma

Volumn 22, Issue SUPPL. 2, 1996, Pages 1-11

  Plunkett, W ^a   Begleiter, A ^b   Liliemark, J O ^c   Reed, J C ^d  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF MANITOBA   (Canada)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^d BURNHAM INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILEUKEMIC AGENT; CHLORAMBUCIL; CLADRIBINE; FLUDARABINE PHOSPHATE; MITOXANTRONE; PROTEIN P53; PURINE DERIVATIVE;

CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DNA CROSS LINKING; DRUG DNA BINDING; DRUG MECHANISM; DRUG SENSITIVITY; HUMAN; HUMAN CELL; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PROTO ONCOGENE; RNA SYNTHESIS; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0030475327     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.3109/10428199609102699     Document Type: Conference Paper

References (4)

1. Keating, M. J., Estey, E., O'Brien, S., Kantarjian, H., Robertson, L. E. and Plunkett, W. (1994a) Clinical experience with fludarabine in leukaemia. Drugs, 47 suppl. 6, 39-49.
2. Keating, M. J., McLaughlin, P., Plunkett, W., Robertson, L. E., O'Brien, S., Gandhi, V., Gregoire, V., Yang, L. and Cabanillas, F. (1994b) Fludarabine - present status and future developments in chronic lymphocytic leukaemia and lymphoma. Ann. Oncol., 5 suppl. 2, 79-83.
3. Keating, M. J., Kantarjian, H., Talpaz, M., Reman, J., Koller, C., Barlogie, B., Velasquez, W., Plunkett, W., Freireich, E. J. and McCredie, K. B. (1989) Fludarabine: a new agent with major activity against chronic lymphocytic leukemia. Blood, 74, 19-25.
4. Keating, M. J., Kantarjian, H., Talpaz, M., Redman, J. and McCredie, K. B. (1988) Fludarabine therapy in chronic lymphocytic leukemia (CLL). Nouv. Rev. Fr. Hematol., 30, 461-466.